The start of chemotherapy until the end of radiotherapy in patients with limited-stage small cell lung cancer
The Korean Journal of Internal Medicine
;
: 449-455, 2013.
Artigo
em Inglês
| WPRIM
| ID: wpr-212579
ABSTRACT
BACKGROUND/AIMS:
Chemotherapy combined with radiation therapy is the standard treatment for limited stage small cell lung cancer (LS-SCLC). Although numerous studies indicate that the overall duration of chemoradiotherapy is the most relevant predictor of outcome, the optimal chemotherapy and radiation schedule for LS-SCLC remains controversial. Therefore we analyzed the time from the start of any treatment until the end of radiotherapy (SER) in patients with LS-SCLC.METHODS:
We retrospectively analyzed 29 patients diagnosed histologically with LS-SCLC and divided them into two groups a short SER group ( 60 days) group. Patients were treated with irinotecan-based chemotherapy and thoracic radiotherapy.RESULTS:
Sixteen patients were in the short SER group and 13 patients were in the long SER group. Short SER significantly prolonged survival rate (p = 0.03) compared with that of long SER. However, no significant differences in side effects were observed.CONCLUSIONS:
Short SER should be considered to improve the outcome of concurrent chemoradiotherapy for LS-SCLC.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fatores de Tempo
/
Distribuição de Qui-Quadrado
/
Razão de Chances
/
Modelos de Riscos Proporcionais
/
Estudos Retrospectivos
/
Resultado do Tratamento
/
Estimativa de Kaplan-Meier
/
Carcinoma de Pequenas Células do Pulmão
/
Quimiorradioterapia
/
Neoplasias Pulmonares
Tipo de estudo:
Estudo de etiologia
/
Estudo observacional
/
Estudo prognóstico
Limite:
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
The Korean Journal of Internal Medicine
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS